Verrica Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Verrica Pharmaceuticals has a total shareholder equity of $19.8M and total debt of $42.9M, which brings its debt-to-equity ratio to 216.9%. Its total assets and total liabilities are $81.6M and $61.8M respectively.
Key information
216.9%
Debt to equity ratio
US$42.87m
Debt
| Interest coverage ratio | n/a |
| Cash | US$69.55m |
| Equity | US$19.76m |
| Total liabilities | US$61.83m |
| Total assets | US$81.60m |
Recent financial health updates
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)
Mar 07Recent updates
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Verrica Pharmaceuticals Should Receive Second CRL Today
May 24Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)
Mar 07Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 06Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook
Dec 17FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA
May 28Verrica Pharmaceuticals EPS beats by $0.32
May 07Verrica Pharma refiles US application for lead candidate in infectious skin disease
Dec 23Verrica Pharma receives final FDA minutes regarding NDA resubmission for VP-102 in molluscum
Nov 17Verrica Pharma' VP-102 successful in mid-stage study for genital warts
Nov 10Verrica Pharmaceuticals EPS misses by $0.02
Nov 09Financial Position Analysis
Short Term Liabilities: VRCA's short term assets ($77.5M) exceed its short term liabilities ($17.0M).
Long Term Liabilities: VRCA's short term assets ($77.5M) exceed its long term liabilities ($44.8M).
Debt to Equity History and Analysis
Debt Level: VRCA has more cash than its total debt.
Reducing Debt: VRCA's debt to equity ratio has increased from 0% to 216.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VRCA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VRCA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 9.7% each year.